|
1) Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113: 2386-93
|
|
|
|
2) Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346: 995-1008
|
|
|
|
|
|
3) Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost. 2009; 7: 322-9
|
|
|
|
|
|
4) Zhu XJ, Shi Y, Peng J, et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood. 2009; 114: 5362-7
|
|
|
|
|
|
5) Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008; 133: 775-87
|
|
|
|
|
|
6) Liu B, Zhao H, Poon MC, et al. Abnormality of CD4(＋)CD25(＋)regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007; 78: 139-43
|
|
|
|
|
|
7) Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008; 112: 1325-8
|
|
|
|
|
|
8) Ling Y, Cao X, Yu Z, et al. Circulating dendritic cells subsets and CD4＋Foxp3＋ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasone. Eur J Haematol. 2007; 79: 310-6
|
|
|
|
|
|
9) Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998; 352: 878
|
|
|
|
|
|
10) Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009; 113: 1231-40
|
|
|
|
|
|
11) Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2004; 124: 91-6
|
|
|
|
|
|
12) Michel M, Khellaf M, Desforges L, et al. Autoimmune thrombocytopenic purpura and Helicobacter pylori infection. Arch Intern Med. 2002; 162: 1033-6
|
|
|
|
|
|
13) Bai Y, Wang Z, Bai X, et al. Cross-reaction of antibody against Helicobacter pylori urease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpura. Int J Hematol. 2009; 89: 142-9
|
|
|
|
|
14) Asahi A, Nishimoto T, Okazaki Y, et al. Helicobacter pylori eradication shifts monocyte Fc gamma receptor balance toward inhibitory Fc gamma RIIB in immune thrombocytopenic purpura patients. J Clin Invest. 2008; 118: 2939-49
|
|
|
|
|
|
15) Kuter DJ. New thrombopoietic growth factors. Blood. 2007; 109: 4607-16
|
|
|
|
|
|
16) Nurden AT, Viallard JF, Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet. 2009; 373: 1562-9
|
|
|
|
|
|
17) Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008; 371: 395-403
|
|
|
|
|
|
18) Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373: 641-8
|
|
|
|
|
|
19) Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009; 113: 3154-60
|
|
|
|
|